[關(guān)鍵詞]
[摘要]
藥物肝毒性是醫(yī)藥界關(guān)注的重要問題。及時(shí)準(zhǔn)確地評(píng)價(jià)藥物的肝毒性,尋找特異性強(qiáng)、靈敏度高的肝毒性生物標(biāo)志物對(duì)新藥研發(fā)及保證臨床用藥安全具有重要意義。針對(duì)傳統(tǒng)的肝毒性生物標(biāo)志物(包括谷氨酸氨基轉(zhuǎn)移酶、天冬氨酸氨基轉(zhuǎn)移酶、谷氨酸脫氫酶等),以及新發(fā)現(xiàn)的生物標(biāo)志物(血清F蛋白、嘌呤核苷磷酸酶、激肽原對(duì)氧磷酶)進(jìn)行綜述,為藥物肝毒性的研究及防治提供參考。
[Key word]
[Abstract]
Drug hepatotoxicity is an important concern in the medical profession. Timely and accurate evaluation of drug hepatotoxicity and specific and sensitive biomarkers of liver toxicity are important for the research and development of new drugs and the safety of clinical medication. In this paper, traditional hepatotoxic biomarkers (including glutamate aminotransferase, aspartateaminotransferase, glutamate dehydrogenase, etc.) as well as newly discovered biomarkers (serum F protein, purine nucleoside phosphate Enzymes, kinin paraoxonase) were reviewed for the study and prevention of drug hepatotoxicity.
[中圖分類號(hào)]
[基金項(xiàng)目]
國(guó)家科技重大新藥創(chuàng)制項(xiàng)目(2015ZX09501004);天津市科技計(jì)劃項(xiàng)目(16PTGCCX00090)